Anagenics Limited · ASX:AN1
Anagenics — Cellmid — Shareholder Meeting (November 2012)
18 slides from Anagenics's shareholder meeting presentation, Nov 23, 2012

Slide 1: Annual General Meeting
Annual General Meeting 23 November 2012 Maria Halasz CEO

Slide 2: Forward-looking statements
This presentation contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of Cellmid to be materially different from the statements in this presentation. Actual res

Slide 3: Cellmid 2012
Cellmid 2012 Significant near term revenue – OTC and diagnostics Strong product pipeline Track record in execution and delivery 3

Slide 4: Significant near term revenue - OTC
Significant near term revenue ‐ OTC • évolis hair growth products with TGA listed claims: • Promotes hair growth • Helps reduce hair loss and thinning • Helps restore the natural growth cycle of the hair by inhibiting FGF‐5 • Australian GMP manufactured • Launched in June 2012 • 700 chemists already

Slide 5: First clinically validated hair growth product in 24 years
First clinically validated hair growth product in 24 years Annual sales: Monoxidil $300M* Finasteride (Propecia) $1,097.6M* *Newport Horizon 5

Slide 6: évolis vs minoxidil
évolis® vs minoxidil évolis Minoxidil No reported side effects, very safe due to clear Poor side effect profile, including lethargy and mode of action depression with long term use No initial shedding Initial shedding often occurs, benefits take 3‐4 months to start Newly grown hair continues to grow

Slide 7: Clinical study results
Clinical study results Quantitative assessment • Rate of hair growth increased by 21% • Hair loss reduced by 35% Qualitative assessment • 74% found the treatment beneficial for hair growth 7

Slide 8: Distribution
Distribution 700 pharmacies Australian pharmacy by EOY 2012 sales 25% of pharmacies (1,300) by EOY 2013 Direct sales force Australian (commissioned agents) direct sales to Targeting 210 salons Advangen hairdressers by EOY 2013 International TVSN in Australia Electronic media and internet sales Group

Slide 9: Strong product pipeline based on powerful patent position
Strong product pipeline based on powerful patent position PRECLINICAL CLINICAL MARKET évolis® hair growth products MK‐ELISA (research market) MK metastatic colorectal diagnostic MK hepatocellular carcinoma diagnostic MK antibodies for inflammation and cancer MK for heart attack 9

Slide 10: Diagnostics pipeline
Diagnostics pipeline • License 1: Quest (Celera) lung cancer screening test • Product expected on market in mid 2013 • Milestone payment and royalties due on and after launch • License 2: Pacific Edge Diagnostics bladder cancer test • Product expected on market in 2013 • Milestone payment and royalt

Slide 11: Therapeutics pipeline
Therapeutics pipeline Animal studies Disease reduced by MK treatment? Preclinical DISEASE Reduced Clinical indication disease in RNAi mAbs and/or MK Inhibitors validation MK‐/‐? YES Osteosarcoma Cancer YES (multiple YES 50% Glioma/glioblastoma cancers) Metastasising carcinomas Surgical Abdominal sur

Slide 12: Track record in execution and delivery
Track record in execution and delivery Dr David King Graeme Kaufman Martin Rogers Maria Halasz 12

Slide 13: 2012: Significant milestones - Funding
2012: Significant milestones Funding • Nov 2011 Rights Issue and Placement of Shortfall (1.4M) • Feb 2012 La Jolla Funding Agreement Termination • April 2012 Cellmid Completes $1.5M Placement • Oct 2012 $748K R&D Tax Credit Received • Oct 2012 $545K Options Rights Issue Completed 13

Slide 14: 2012: Significant milestones - Business
2012: Significant milestones Business • Dec 2011 Completed Midkine Study for Normal Reference Range • Feb 2012 TGA Registration and Launch of Cellmid's évolis Products • Mar 2012 Annual Report on Celera (Quest) License • Mar 2012 Media Launch of évolis Hair Products • April 2012 Commercial website l

Slide 15: 2012: Significant milestones - Patent and Board
2012: Significant milestones Patent • April 2012 USA Antibody Patent for Adhesion Allowed • May 2012 USA Treg Antibody Patent Allowed • July 2012 USA Midkine Ischemia Patent Allowed Board • Aug 2012 Appointment of Graeme Kaufman • Sept 2012 Appointment of Martin Rogers 15

Slide 16: 2013 Business outlook
2013 Business outlook Advangen • Growing distribution and sales for évolis in Australia and overseas • Increasing brand awareness of évolis • Building distribution for Advangen range (hairdressing salons) Therapeutic programs • Preclinical efficacy studies progressed and lead indication selected for

Slide 17: Cellmid 2013
Cellmid 2013 Opportunity to increase revenue from multiple channels Convert patent portfolio into products Increase market recognition 17

Slide 18: Thank you
Thank you www.cellmid.com.au Maria Halasz CEO (612) 9299 0311 halasz@cellmid com.au 18
Source: Internet Archive copy of anagenics.com
More decks from Anagenics Limited
H1 2026 Earnings Presentation12 slides · Feb 25, 2026
Shareholder Meeting (November 2025)14 slides · Nov 25, 2025
FY2025 Earnings Presentation15 slides · Aug 28, 2025
Q3 2025 Earnings Presentation15 slides · May 5, 2025
Shareholder Meeting (November 2024)12 slides · Nov 26, 2024
FY2024 Earnings Presentation14 slides · September 2024